Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2014 1
2015 1
2016 1
2017 2
2019 4
2020 6
2021 5
2022 5
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis.
Imai T, Kojima Y, Shimoi T, Aiba H, Okuma HS, Saito A, Kita S, Yamamoto K, Maejima A, Nishikawa T, Sudo K, Noguchi E, Yoshida A, Matsui Y, Iwata S, Kobayashi E, Kawai A, Udagawa R, Fujiwara Y, Yonemori K. Imai T, et al. Among authors: yamamoto k. Anticancer Res. 2024 May;44(5):2125-2132. doi: 10.21873/anticanres.17018. Anticancer Res. 2024. PMID: 38677749
Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.
Miyakoshi J, Yazaki S, Shimoi T, Onishi M, Saito A, Kita S, Yamamoto K, Kojima Y, Sumiyoshi-Okuma H, Nishikawa T, Sudo K, Noguchi E, Murata T, Shiino S, Takayama S, Suto A, Fujiwara Y, Yoshida M, Yonemori K. Miyakoshi J, et al. Among authors: yamamoto k. Virchows Arch. 2023 Dec;483(6):855-863. doi: 10.1007/s00428-023-03634-2. Epub 2023 Sep 5. Virchows Arch. 2023. PMID: 37668667
Lymphocyte-to-monocyte ratio as a prognostic and potential tumor microenvironment indicator in advanced soft tissue sarcoma treated with first-line doxorubicin therapy.
Watanabe S, Shimoi T, Nishikawa T, Kawachi A, Okuma HS, Tokura M, Yazaki S, Mizoguchi C, Arakaki M, Saito A, Kita S, Yamamoto K, Kojima Y, Sudo K, Noguchi E, Yoshida A, Kawai A, Fujiwara Y, Yonemori K. Watanabe S, et al. Among authors: yamamoto k. Sci Rep. 2023 Jul 3;13(1):10734. doi: 10.1038/s41598-023-37616-w. Sci Rep. 2023. PMID: 37400504 Free PMC article.
Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer.
Sanomachi T, Okuma HS, Kitadai R, Kawachi A, Yazaki S, Tokura M, Arakaki M, Saito A, Kita S, Yamamoto K, Maejima A, Kojima Y, Nishikawa T, Sudo K, Shimoi T, Noguchi E, Fujiwara Y, Sugino H, Shiino S, Suto A, Yoshida M, Yonemori K. Sanomachi T, et al. Among authors: yamamoto k. Front Oncol. 2023 Mar 27;13:1157789. doi: 10.3389/fonc.2023.1157789. eCollection 2023. Front Oncol. 2023. PMID: 37051545 Free PMC article.
Changes in HER3 expression profiles between primary and recurrent gynecological cancers.
Kojima Y, Sudo K, Yoshida H, Yazaki S, Tokura M, Mizoguchi C, Okuma HS, Kita S, Yamamoto K, Nishikawa T, Noguchi E, Shimoi T, Tanase Y, Uno M, Ishikawa M, Kato T, Koyama K, Kobayashi M, Kakegawa T, Fujiwara Y, Yonemori K. Kojima Y, et al. Among authors: yamamoto k. Cancer Cell Int. 2023 Feb 3;23(1):18. doi: 10.1186/s12935-022-02844-z. Cancer Cell Int. 2023. PMID: 36737733 Free PMC article.
Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
Yazaki S, Shimoi T, Yoshida M, Sumiyoshi-Okuma H, Arakaki M, Saito A, Kita S, Yamamoto K, Kojima Y, Nishikawa T, Tanioka M, Sudo K, Noguchi E, Murata T, Shiino S, Takayama S, Suto A, Ohe Y, Fujiwara Y, Yonemori K. Yazaki S, et al. Among authors: yamamoto k. Breast Cancer Res Treat. 2023 Jan;197(2):287-297. doi: 10.1007/s10549-022-06787-x. Epub 2022 Nov 16. Breast Cancer Res Treat. 2023. PMID: 36385236 Free PMC article.
33 results